PharmaCorp Rx Inc. PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 75.74% | 87.69% | 75.52% | 330.62% | 1,391.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 75.74% | 87.69% | 75.52% | 330.62% | 1,391.60% |
| Cost of Revenue | 74.15% | 93.01% | 73.78% | 308.63% | 1,257.98% |
| Gross Profit | 78.14% | 79.88% | 78.35% | 366.94% | 1,652.70% |
| SG&A Expenses | 53.43% | 115.68% | 192.24% | 52.14% | 174.49% |
| Depreciation & Amortization | 76.89% | 96.71% | 79.24% | 190.29% | 731.10% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.97% | 100.44% | 106.89% | 136.47% | 421.46% |
| Operating Income | 63.85% | -123.52% | -278.39% | 55.71% | 45.94% |
| Income Before Tax | 138.82% | -65.76% | -188.32% | 56.60% | 62.10% |
| Income Tax Expenses | -120.75% | -108.26% | 418.30% | -2,383.33% | 57,200.00% |
| Earnings from Continuing Operations | 131.42% | -47.80% | -222.37% | 58.55% | 35.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5,575.00% | -59.30% | -184.11% | -1,123.08% | 200.00% |
| Net Income | 107.89% | -53.20% | -220.58% | 56.62% | 36.24% |
| EBIT | 63.85% | -123.52% | -278.39% | 55.71% | 45.94% |
| EBITDA | 224.05% | -35.36% | -168.34% | 71.24% | 76.33% |
| EPS Basic | 104.17% | -64.29% | -195.65% | 58.73% | 69.23% |
| Normalized Basic EPS | 88.89% | -84.62% | -169.23% | 53.85% | 81.63% |
| EPS Diluted | 104.17% | -69.23% | -195.65% | 58.73% | 69.23% |
| Normalized Diluted EPS | 88.89% | -83.33% | -169.23% | 53.85% | 81.63% |
| Average Basic Shares Outstanding | 48.41% | 48.41% | 26.48% | 3.66% | 110.80% |
| Average Diluted Shares Outstanding | 56.27% | 46.54% | 26.48% | 3.66% | 110.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |